Future studies should focus on further elucidating the downstream effects of dysregulated lipolysis in the context of obesity-related pathologies, as well as exploring potential therapeutic interventions targeting the ZFP36/RNF128/Sirt1 pathway to mitigate metabolic dysfunction. The gene discussed is ZFP36; the disease is obesity disorder.